NEXGEL, Inc. (NXGL), a provider of hydrogel-based healthcare and consumer products, reported financial results for the second quarter ended June 30, 2026, highlighting progress in BioNX Surgical division and hospital channel expansion.
NEXGEL, Inc. (NXGL), a healthcare, beauty, and over-the-counter products manufacturer, Monday, announced that it has appointed Ian Blackman as its Chief Financial Officer. Blackman is a seasoned finance executive with over 30 years of experience and was most recently the finance chief of McIntosh...
NEXGEL, Inc. (NXGL) on Wednesday announced the signing of a definitive agreement to license and acquire a portfolio of six commercial-stage regenerative biomaterial products from Celularity Inc (CELU). Following the news, NXGL is plunging 10.16% to $0.85, and CELU is down 8.27% to $1.27. NEXGEL...
NEXGEL Inc. (NXGL), a provider of medical and over-the-counter products, including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, expects revenue growth of over 100% in 2024 and is optimistic about its outlook for 2025.
The following were some of the top movers in after-hours trading on Friday.
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.